Skip to main content
. Author manuscript; available in PMC: 2016 Dec 19.
Published in final edited form as: Mol Pharm. 2015 May 8;12(6):1929–1938. doi: 10.1021/mp5006917

Figure 6.

Figure 6

Biodistribution of 68Ga-DOTA-PEG4-LLP2A (5.55 MBq, 277 ng) in B16F10 tumor-bearing mice at 1 h postinjection, with or without excess LLP2A-PEG4 as a blocking agent (n = 4) (A). Tumor/blood and tumor/muscle ratio of 68Ga-DOTA-PEG4-LLP2A (B).